NCT05930249 is a NA clinical trial of Personalized multidomain intervention in Cognitive Impairment, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05930249?

NCT05930249 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05930249?

Interventions in NCT05930249: Personalized multidomain intervention.

What condition does NCT05930249 study?

NCT05930249 studies Cognitive Impairment, Stroke, Dementia.

Is NCT05930249 still recruiting?

NCT05930249 is currently status unknown. Last updated 5 July 2023.

Last reviewed 2023-07-05 · How we verify

NCT05930249

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of a fNIRS-based Personalized Multi-domain Intervention on Cognitive in Elderly Population With High Risk of Stroke

Status unknown NA Last updated 5 July 2023

What this trial tests

NA trial testing Personalized multidomain intervention in Cognitive Impairment in 264 participants. Status unknown.

Timeline

1 July 2023

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	264
Start date	1 July 2023
Primary completion	1 December 2023
Estimated completion	1 December 2023
Sites	1 location across China

Drugs / interventions tested

Personalized multidomain intervention

Conditions studied

Cognitive Impairment — all drugs for Cognitive Impairment →
Stroke — all drugs for Stroke →
Dementia — all drugs for Dementia →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 45 to 74, any sex, with Cognitive Impairment or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This functional near-infrared spectroscopy-based personalized multidomain intervention study aims to prevent cognitive impairment and reduce dementia and cerebrovascular events in 45-74 years old persons with high risk of stroke in China. The primary outcome is 6-months change in global cognitive score measured by a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network protocol. The investigators hypothesize that the intervention based on functional near-infrared spectroscopy will prevent cognitive decline by the initial 6-months intervention. The long-term primary outcome is the development of dementia and cerebrovascular events during a total of 2 years' follow-up. The investigators hypothesize that the functional near-infrared spectroscopy-based personalized intervention may reduce the 2-year risk of dementia and cerebrovascular events, mainly through the improvement in vascular risk factors control, social activity, and cognitive training activities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cognitive Impairment

Currently open trials in the same condition.

NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05930249 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 5 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05930249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing